Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

4-AcO-DET: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Brack
effects template
>David Hedlund
{{Experience reports|erowid_experience_substance_label=4-AcO-DET}}
 
(45 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SubstanceBox/4-AcO-DET}}
{{SubstanceBox/4-AcO-DET}}
{|
|-
|-
| ''[[4-AcO-DET/Summary|Summary sheet: 4-AcO-DET]]''
|}
'''4-AcO-DET''' ('''4-Acetoxy-N,N-diethyltryptamine''', '''ethacetin''') is an obscure synthetic [[psychoactive class::psychedelic]] [[chemical class::tryptamine]]. There is very little information on the human pharmacology or toxicity of 4-AcO-DET, although analytical methods have been developed for its detection.<ref>http://www.sciencedirect.com/science/article/pii/S0039914008005808</ref><ref>http://link.springer.com/article/10.1007%2Fs00044-011-9794-y</ref> Today it is either used recreationally as a [[designer drug]] or as an [[entheogen]]ic compound and is typically acquired through the use of online [[research chemical]] vendors. It remains relatively rare and has very little documented history of human usage.


4-AcO-DET is the acetylated form of [[4-HO-DET]] (also known as ethocin) and is a higher homolog of [[4-AcO-DMT]] and [[4-AcO-MET]]. Like the aforementioned compounds, it is commonly hypothesized to act principally as a prodrug for their respective hydrolyzed counterparts (e.g. [[4-HO-DMT]], [[4-HO-MET]] and [[4-HO-DET]]). In theory, they would become inactive until they are deacetylated in the body, although there is on-going discussion as to whether they might display their own intrinsic activity.{{citation needed}}
'''4-AcO-DET''' ('''4-Acetoxy-N,N-diethyltryptamine''', '''ethacetin''') is a lesser-known novel [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. It is chemically related to [[psilocin]] and part of a series of substituted tryptamines that includes 4-AcO-MET and 4-AcO-DMT.  
 
Today it is either used recreationally as a [[designer drug]] or as an [[entheogen]]ic compound and is typically acquired through the use of online [[research chemical]] vendors.
 
There is very little data on the human pharmacology or toxicity of 4-AcO-DET, although analytical methods have been developed for its detection.<ref>{{cite journal|title=Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry|pmid=19084633|doi=10.1016/j.talanta.2008.07.062|last1=Takahashi|first1=M.|last2=Nagashima|first2=M.|last3=Suzuki|first3=J.|last4=Yasuda|first4=I|last5=Yoshida|first5=T.|volume=77|issue=4|date=February 15, 2009|pages=1245-1272|issn=0039-9140|eissn=1873-3573|oclc=01767116}}</ref> It remains relatively rare and has very little documented history of human usage. It is highly advised to use [[harm reduction practices]] if using this substance.
 
==Chemistry==
==Chemistry==
4-AcO-DET, or 4-Acetoxy-N.N-diethyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 4-AcO-DET is substituted at R<sub>4</sub> of its indole heterocycle with an acetoxy (AcO) functional group CH<sub>3</sub>COO−. It also contains isopropyl and methyl chains bound to the terminal amine R<sub>N</sub> of its tryptamine backbone ([[DET]]).  
4-AcO-DET, or 4-Acetoxy-N.N-diethyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 4-AcO-DET is substituted at R<sub>4</sub> of its indole heterocycle with an acetoxy (AcO) functional group CH<sub>3</sub>COO−. It also contains two ethyl chains bound to the terminal amine R<sub>N</sub> of its tryptamine backbone ([[DET]]).  


4-AcO-DET is the N-substituted diethyl homolog of [[4-HO-DMT]] (psilocin). 4-AcO-DET is the acetate ester analog of [[DET]] and the N-substituted diethyl analog of [[4-AcO-DMT]].<ref>4-Acetoxy-DET - PubChem | https://pubchem.ncbi.nlm.nih.gov/compound/3-_2-_Diethylamino_ethyl_-1H-indol-4-yl_acetate#section=Top</ref>
4-AcO-DET is the N-substituted diethyl homolog of [[4-HO-DMT]] (psilocin). 4-AcO-DET is the acetate ester analog of [[DET]] and the N-substituted diethyl analog of [[4-AcO-DMT]].<ref>{{cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/24801867|title=Compound Summary - 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate|website=PubChem|access-date=July 18, 2020}}</ref> It is a higher homolog of [[4-AcO-DMT]] and [[4-AcO-MET]].


==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
4-substituted acetylated tryptamines such as 4-AcO-DET, [[4-AcO-MET]], and [[4-AcO-DMT]] are hypothesized to principally act as a [[prodrug]] for their respective hydrolyzed counterparts (e.g. [[4-HO-DMT]], [[4-HO-MET]] and [[4-HO-DET]]). In theory, they would become inactive until they are deacetylated in the body, although there is on-going discussion as to whether they might display their own intrinsic activity.{{citation needed}}
Like with most [[psychedelic]] tryptamines, 4-AcO-DET is thought to act principally as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The psychedelic effects are believed to come from 4-AcO-DET's binding efficacy at the 5-HT<sub>2A</sub> receptors.  
Like with most [[psychedelic]] tryptamines, 4-AcO-DET is thought to act principally as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The psychedelic effects are believed to come from 4-AcO-DET's binding efficacy at the 5-HT<sub>2A</sub> receptors.  


Line 21: Line 23:
==Subjective effects==
==Subjective effects==
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base


{{effects/base
|{{effects/physical|
|{{effects/physical|
*'''[[Effect::Sedation]]''' and '''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, 4-AcO-DET is typically relaxing, stoning and mildly sedating, although it can also sometimes be very stimulating and give users a "wired" feeling. This sense of sedation is often accompanied by uncontrollable yawning.
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of 4-AcO-DET can be described as a pleasurable, warm, soft and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached. Unlike other 4-substituted tryptamines, 4-AcO-DET is capable of being more stimulating and [[anxiety]]-inducing.
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Bodily pressures]]'''
*'''[[Effect::Bodily pressures]]'''
*'''[[Effect::Excessive yawning]]'''
*'''[[Effect::Excessive yawning]]'''
*'''[[Effect::Sedation]]''' and '''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the tripper, 4-AcO-DET is typically relaxing, stoning and mildly sedating, although it can also sometimes be very stimulating and give users a "wired" feeling. This sense of sedation is often accompanied by uncontrollable yawning.
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of 4-AcO-DET can be described as a pleasurable, warm, soft and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached. Unlike other 4-substituted tryptamines, 4-AcO-DET is capable of being more stimulating and [[anxiety]]-inducing.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Runny nose]]'''
*'''[[Effect::Runny nose]]'''
Line 72: Line 74:


*'''[[Effect::Transformations]]'''
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their [[Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, [[Effect::geometry]]-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their [[Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, [[Effect::geometry]]-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.


}}
}}
Line 83: Line 85:
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Delusions]]'''
*'''[[Effect::Delusion]]'''
*'''[[Effect::Subconscious communication]]'''
*'''[[Effect::Autonomous voice communication]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Emotionality enhancement]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Enhancement and suppression cycles]]''' - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 - 60 minutes.
*'''[[Effect::Enhancement and suppression cycles]]''' - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 - 60 minutes.
*'''[[Effect::Feelings of interdependent opposites]]'''
*'''[[Effect::Feelings of interdependent opposites]]'''
Line 113: Line 115:


===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
{{Experience reports|erowid_experience_substance_label=4-AcO-DET}}
* [https://www.erowid.org/experiences/subs/exp_4AcODET.shtml Erowid Experience Vaults: 4-AcO-DET]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 4-AcO-DET use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because 4-AcO-DET is a [[research chemical]] with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.  
The toxicity and long-term health effects of recreational 4-AcO-DET has not been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]].  
This is because 4-AcO-DET is a [[research chemical]] with a very limited history of human usage.  
However, it is assumed to have a similar toxicity profile as [[psilocybin]] due to their structural similarity.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
Anecdotal reports from those who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
 
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.


===Tolerance and addiction potential===
===Tolerance and addiction potential===
4-AcO-DET is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with regular consumption. Like with most [[psychedelics]], it is most often thought to be self-regulating.  
Although no formal studies have been conducted, it is believed that 4-AcO-DET is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use.  


Tolerance to the effects of 4-AcO-DET are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 4-AcO-DET presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 4-AcO-DET all psychedelics will have a reduced effect.
Tolerance to the effects of 4-AcO-DET is built [[Time to full tolerance::almost immediately after ingestion]].  
After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption).  
4-AcO-DET presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 4-AcO-DET all psychedelics will have a reduced effect.


==Legal issues==
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Psychedelics}}
 
==Legal status==
{{LegalStub}}
{{LegalStub}}
Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.  
Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.


*'''United Kingdom''' - 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug [[4-HO-DET]].<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3</ref>, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e</ref>
*'''Germany''': Because it is an ester of DET, 4-AcO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I)<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Betäubungsmittelgesetz (BtMG) Anlage I|trans-title=Narcotics Act (BtMG) Schedule I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of January 24, 1974.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl174s0097.pdf|title=Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe|publisher=Bundesanzeiger Verlag [Federal Gazette]|language=de|eissn=0344-7634|page=97|work=Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6|date=January 17, 1974|publication-date=January 23, 1974}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Betäubungsmittelgesetz (BtMG) § 29|trans-title=Narcotics Act (BtMG) § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref>
*'''United States''' - 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of [[psilocin]] (''4-HO-DMT'') which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.{{citation needed}}
*'''Japan''': 4-AcO-DET is a controlled substance in Japan effective July 29th, 2015.<ref>{{Citation | title=危険ドラッグの成分4物質を新たに指定薬物に指定 | publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)] | url=https://www.mhlw.go.jp/stf/houdou/0000092698.html | language=japanese | access-date=2 May 2022}}</ref>
*'''Switzerland''': 4-AcO-DET is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Sweden''':  4-AcO-DET was classified under the Act on the Prohibition of Certain Goods Dangerous to Health on November 1, 2005, making it illegal to sell or possess.<ref name="notisum">{{cite web|url=http://www.notisum.se/rnp/sls/sfs/20050733.pdf|date=October 6, 2005|publication-date=October 18, 2005|title=Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor|publisher=Läkemedelsverket [Medical Products Agency]|id=SFS 2005:733|language=sv|work=Svensk författningssamling|issn=1101-5225}}</ref>
*'''Turkey:''' 4-AcO-DET is a classed as drug and is illegal to possess, produce, supply, or import.<ref>{{cite web|title=Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr}}</ref><ref>{{cite web|title=Kararnamenin Eki: Liste|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr|id=2013/5742|work=Resmî Gazete, Sayı: 28893}}</ref>
*'''United Kingdom''': 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug [[4-HO-DET]], which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=January 7, 2020|publisher=UK Government}}</ref>
*'''United States''': 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of [[psilocin]] (''4-HO-DMT'') which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.{{citation needed}}


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Research chemical]]
*[[Research chemical]]
*[[Hallucinogen]]
*[[Tryptamine]]
*[[Tryptamine]]
*[[4-HO-DET]]
*[[4-HO-DET]]
Line 143: Line 161:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/4-AcO-DET 4-AcO-DET (Wikipedia)]
*[https://en.wikipedia.org/wiki/4-AcO-DET 4-AcO-DET (Wikipedia)]
*[https://www.erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det.shtml 4-AcO-DET (Erowid)]
*[https://erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det.shtml 4-AcO-DET (Erowid Vault)]
*[http://drugs.tripsit.me/4-ho-det 4-AcO-DET (TripSit)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5368 4-AcO-DET (Isomer Design)]
 
===Discussion===
 
*[https://www.bluelight.org/xf/threads/101364 The Big & Dandy 4-AcO-DET Thread (Bluelight)]


==References==
==References==
<references/>
<references />
[[Category:Substance]]
 
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Tryptamine]]
[[Category:Psychedelic]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Psychedelic]]
[[Category:Tryptamine]]


{{#set:Featured=true}}
{{#set:Featured=true}}

Latest revision as of 14:27, 2 July 2025

Summary sheet: 4-AcO-DET
4-AcO-DET
Chemical Nomenclature
Common names 4-AcO-DET, 4-Acetoxy-DET, Ethacetin
Substitutive name 4-Acetoxy-N,N-diethyltryptamine
Systematic name 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 10 - 15 mg
Common 15 - 20 mg
Strong 20 - 35 mg
Heavy 35 mg +
Duration
Total 4 - 7 hours
Onset 20 - 60 minutes
Come up 1 - 1.5 hours
Peak 1.5 - 3 hours
Offset 1 - 2 hours
After effects 2 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


4-AcO-DET (4-Acetoxy-N,N-diethyltryptamine, ethacetin) is a lesser-known novel psychedelic substance of the tryptamine class. It is chemically related to psilocin and part of a series of substituted tryptamines that includes 4-AcO-MET and 4-AcO-DMT.

Today it is either used recreationally as a designer drug or as an entheogenic compound and is typically acquired through the use of online research chemical vendors.

There is very little data on the human pharmacology or toxicity of 4-AcO-DET, although analytical methods have been developed for its detection.[1] It remains relatively rare and has very little documented history of human usage. It is highly advised to use harm reduction practices if using this substance.

Chemistry

4-AcO-DET, or 4-Acetoxy-N.N-diethyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-AcO-DET is substituted at R4 of its indole heterocycle with an acetoxy (AcO) functional group CH3COO−. It also contains two ethyl chains bound to the terminal amine RN of its tryptamine backbone (DET).

4-AcO-DET is the N-substituted diethyl homolog of 4-HO-DMT (psilocin). 4-AcO-DET is the acetate ester analog of DET and the N-substituted diethyl analog of 4-AcO-DMT.[2] It is a higher homolog of 4-AcO-DMT and 4-AcO-MET.

Pharmacology

Further information: Serotonergic psychedelic

4-substituted acetylated tryptamines such as 4-AcO-DET, 4-AcO-MET, and 4-AcO-DMT are hypothesized to principally act as a prodrug for their respective hydrolyzed counterparts (e.g. 4-HO-DMT, 4-HO-MET and 4-HO-DET). In theory, they would become inactive until they are deacetylated in the body, although there is on-going discussion as to whether they might display their own intrinsic activity.[citation needed]

Like with most psychedelic tryptamines, 4-AcO-DET is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-AcO-DET's binding efficacy at the 5-HT2A receptors.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects


Experience reports

There are currently 0 experience reports describing the effects of this substance in our experience index. You can also submit your own experience report using the same link.

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4-AcO-DET has not been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-DET is a research chemical with a very limited history of human usage. However, it is assumed to have a similar toxicity profile as psilocybin due to their structural similarity.

Anecdotal reports from those who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is believed that 4-AcO-DET is not habit-forming and the desire to use it can actually decrease with use.

Tolerance to the effects of 4-AcO-DET is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-AcO-DET presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 4-AcO-DET all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • [[Wikipedia:Lithium_(medication)|DangerousInteraction::Lithium]] - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 4-AcO-DET. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is well-documented to lower the seizure threshold[3] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.

  • Germany: Because it is an ester of DET, 4-AcO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[4] as of January 24, 1974.[5] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[6]
  • Japan: 4-AcO-DET is a controlled substance in Japan effective July 29th, 2015.[7]
  • Switzerland: 4-AcO-DET is a controlled substance specifically named under Verzeichnis E.[8]
  • Sweden: 4-AcO-DET was classified under the Act on the Prohibition of Certain Goods Dangerous to Health on November 1, 2005, making it illegal to sell or possess.[9]
  • Turkey: 4-AcO-DET is a classed as drug and is illegal to possess, produce, supply, or import.[10][11]
  • United Kingdom: 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug 4-HO-DET, which is a Class A drug as a result of the tryptamine catch-all clause.[12]
  • United States: 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

Discussion

References

  1. Takahashi, M.; Nagashima, M.; Suzuki, J.; Yasuda, I; Yoshida, T. (February 15, 2009). "Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry". 77 (4): 1245–1272. doi:10.1016/j.talanta.2008.07.062. eISSN 1873-3573. ISSN 0039-9140. OCLC 01767116. PMID 19084633. 
  2. "Compound Summary - 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate". PubChem. Retrieved July 18, 2020. 
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  4. "Betäubungsmittelgesetz (BtMG) Anlage I" [Narcotics Act (BtMG) Schedule I] (in Deutsch). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  5. "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in Deutsch). Bundesanzeiger Verlag [Federal Gazette] (published January 23, 1974). January 17, 1974. p. 97. eISSN 0344-7634. 
  6. "Betäubungsmittelgesetz (BtMG) § 29" [Narcotics Act (BtMG) § 29] (in Deutsch). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  7. 危険ドラッグの成分4物質を新たに指定薬物に指定 (in japanese), 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)], retrieved 2 May 2022 
  8. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  9. "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF). Svensk författningssamling (in svenska). Läkemedelsverket [Medical Products Agency] (published October 18, 2005). October 6, 2005. ISSN 1101-5225. SFS 2005:733. 
  10. "Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742" (in Türkçe). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013. 
  11. "Kararnamenin Eki: Liste" (PDF). Resmî Gazete, Sayı: 28893 (in Türkçe). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013. 2013/5742. 
  12. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.